Supporting safe practices for low-dose methotrexate – NMS 2021
Inconsistent practices and information about the use of low-dose methotrexate for inflammatory diseases results in unfounded patient and health professional…
Assessment and evaluation of high cost medicines in Australian public hospitals
Poster presentation at SHPA Medicines Management Conference 2015 aiming to describe the decision-making process for access to High Cost Medicines…
Overseeing Biosimilar Use: Guiding Principles for the governance of biological and biosimilar medicines in Australian hospitals
Poster presentation at SHPA Medicines Management Conference 2015. This poster aims to provide guidance for good governance and decision-making in…
Supporting the Quality Use of Medicines across the acute-care sector
Editorial article in the Internal Medicine Journal 2015
Off -label prescribing – Letter to the Editor MJA
Rethinking medicines decision-making for off-label use of medicines conference presentation
Poster presentation at ASCEPT conference in 2013. CATAG developed a consensus framework to support the quality use of off-label medicines…
Prospective data collection of off-label use of rituximab in Australian public hospitals
Poster presentation at SHPA conference 2013. Aims to provide a snapshot of the extent of off-label rituximab use.
SMART PROCESSES: Development of National Guiding Principles for Drug and Therapeutics Committees
Poster presentation at SHPA Medicines Management Conference 2013
SMART DECISIONS: Development of National Guiding Principles for Off-label Use of Medicines
Poster presentation at SHPA Medicines Management Conference 2013.
Prospective data collection of off-label use of rituximab in Australian public hospitals
Original article in the Internal Medicine Journal 2013 on off-label use of rituximab in Australian public hospitals.